Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

NCT00321620 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1904

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases

Interventions

DRUG: zoledronic acid
BIOLOGICAL: denosumab

Sponsor

Amgen